Mercado mundial de diagnóstico epigenético: tendencias de la industria y pronóstico hasta 2031

Análisis y tamaño del mercado de diagnóstico epigenético

En el ámbito de la salud cardiovascular, los diagnósticos epigenéticos desempeñan un papel crucial a la hora de identificar a las personas con riesgo de desarrollar enfermedades cardíacas. Mediante el análisis de los patrones de metilación del ADN y las modificaciones de las histonas asociadas a enfermedades cardiovasculares como la hipertensión , la aterosclerosis y la enfermedad de las arterias coronarias , estas pruebas pueden proporcionar indicaciones tempranas de susceptibilidad. Los marcadores epigenéticos ofrecen información sobre los mecanismos moleculares subyacentes que contribuyen a la enfermedad cardiovascular, lo que permite estrategias de prevención e intervención más específicas. La elaboración de perfiles epigenéticos puede ayudar a controlar la progresión de la enfermedad y evaluar la eficacia de las intervenciones, lo que orienta los enfoques de tratamiento personalizados para mejorar los resultados de los pacientes.

El tamaño del mercado global de diagnóstico de epigenética se valoró en USD 13,28 mil millones en 2023 y se proyecta que alcance los USD 57,42 mil millones para 2031, con una CAGR del 20,20% durante el período de pronóstico de 2024 a 2031.

Además de la información sobre escenarios de mercado como valor de mercado, tasa de crecimiento, segmentación, cobertura geográfica y actores principales, los informes de mercado seleccionados por Data Bridge Market Research también incluyen análisis profundo de expertos, epidemiología de pacientes, análisis de canalización, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado       

Market Definition

Epigenetics diagnostics involves the study of chemical modifications to DNA and proteins that regulate gene expression without altering the underlying genetic code. By analyzing these epigenetic markers, such as DNA methylation and histone modifications, diagnostic tests can provide insights into an individual's susceptibility to certain diseases, predict disease progression, and inform personalized treatment strategies.

Epigenetics Diagnostic Market Dynamics

Drivers                                                                                          

• Escalating Prevalence of Chronic Diseases

Epigenetic alterations play a crucial role in the development and progression of chronic diseases, such as cancer, cardiovascular disorders, and neurological conditions that offer valuable insights into their molecular mechanisms. As healthcare systems worldwide grapple with the burden of chronic illnesses, there is a growing need for early detection and personalized treatment strategies, which epigenetics diagnostics can fulfill. Epigenetic biomarkers associated with disease risk and progression empowers clinicians to implement proactive interventions, thereby enhancing patient outcomes and optimizing healthcare efficiency. Consequently, the increasing incidence of chronic diseases fuels the demand for epigenetics diagnostics, driving market growth and innovation in the field.

• Rising Advancements in Technology

Innovations such as next-generation sequencing (NGS), high-throughput DNA methylation arrays, and single-cell epigenomics platforms have revolutionized the accuracy, speed, and cost-effectiveness of epigenetic analysis. These technologies enable comprehensive profiling of epigenetic modifications across the genome, offering deeper insights into disease mechanisms and biomarker discovery. Moreover, the integration of bioinformatics tools facilitates data analysis and interpretation, enhancing the clinical utility of epigenetics diagnostics. These technological advancements expand the scope of epigenetic research and drive the development of novel diagnostic assays and personalized treatment strategies, driving market growth.

Opportunities

• Growing Awareness of Personalized Medicine

Healthcare providers and patients recognize the importance of individual genetic and epigenetic variations in disease susceptibility, progression, and treatment response, and there's a heightened demand for diagnostic tools capable of offering tailored insights. Epigenetic diagnostic tests have the ability to assess epigenetic modifications, which influence gene expression and hold immense promise in enabling personalized treatment strategies across various medical specialties. This awareness fosters greater adoption of epigenetics diagnostic tests among clinicians and patients, driving market growth as healthcare systems increasingly prioritize precision medicine approaches to improve patient outcomes and optimize healthcare delivery.

• High Strategic Collaborations

Strategic collaborations typically involve partnerships between diagnostic companies, research institutions, and pharmaceutical firms, pooling together expertise, resources, and technologies. By joining forces, stakeholders can accelerate the development and commercialization of innovative epigenetic biomarkers and diagnostic assays. These collaborations facilitate access to diverse patient cohorts and clinical datasets, enabling robust validation and refinement of diagnostic products. Moreover, strategic partnerships enhance market penetration by leveraging established distribution networks and regulatory expertise, ultimately catalyzing the adoption of epigenetics diagnostics in clinical practice.

Restraints/Challenges

• High Complexity of Interpreting Epigenetic Data

Epigenetic modifications involve intricate molecular mechanisms that regulate gene expression, and their correlation with disease states can be nuanced and context-dependent. Deciphering these complex relationships requires advanced computational algorithms and interdisciplinary expertise, which may not be readily available in clinical practice. Moreover, the lack of standardized protocols for data analysis and interpretation further exacerbates the challenge, leading to variability in results and hindering the reliability and clinical utility of epigenetics diagnostics.

• High Costs Constraints

High costs encompass the initial investment in sophisticated laboratory equipment and infrastructure and ongoing expenses related to reagents, consumables, and data analysis software. Additionally, the need for specialized expertise in epigenetic assay development and interpretation further adds to the overall cost burden. Consequently, the high costs and specialized expertise required for epigenetics diagnostic tests can restrict their affordability and accessibility, especially in resource-constrained healthcare environments. This limitation impedes market adoption and hinders patient access to cutting-edge diagnostic technologies.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2023, Agilent Technologies, Inc. announced the acquisition of Avida Biomed, a company specializing in the development of target enrichment workflows tailored for clinical researchers utilizing Next-Generation Sequencing (NGS) methods to investigate cancers. This strategic acquisition aligns with Agilent's commitment to advancing precision medicine by enhancing its portfolio of genomic analysis solutions. Avida Biomed's expertise in target enrichment workflows is anticipated to complement Agilent's existing capabilities, facilitating more efficient and accurate genomic analysis in cancer research and diagnostics
• In February 2022, Zenith Epigenetics Ltd. marked a significant milestone by administering the first dose of a combination therapy, ZEN-3694 (a BET inhibitor), along with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitors OPDIVO and YERVOY. This trial, sponsored by the National Cancer Institute (NCI), aimed to evaluate the efficacy of the combination in treating solid tumor cancers. The approach leverages the synergistic potential of epigenetic modulation and immune checkpoint blockade to enhance anti-cancer immune responses and potentially improve patient outcomes

Epigenetics Diagnostic Market Scope

The market is segmented on the basis of product, application, technology, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Enzymes
• Instruments and Consumables
• Kits
• Reagents

Application

• Oncology
• Metabolic Diseases
• Developmental Biology
• Immunology
• Cardiovascular Diseases
• Others

Technology

• DNA Methylation
• Histone Methylation
• Others

End User

• Academic and Research Institutes
• Pharmaceutical Companies and Biotechnology Companies
• Contract Research Organizations (CROs)

Epigenetics Diagnostic Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, product, application, technology, and end user as referenced above.

The countries covered in the market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Kuwait, Egypt, and rest of Middle East and Africa.   

North America is expected to dominate the market, driven by rising investments in research and development capabilities bolstered by government initiatives and advancements in healthcare infrastructure across the region. The region's commitment to innovation and technological advancement, coupled with a favorable regulatory environment, positions it as a hub for the development and adoption of cutting-edge healthcare solutions. These factors collectively contribute to North America's dominance in driving growth and innovation within the industry, paving the way for enhanced healthcare outcomes and patient care.

Asia-Pacific is expected to witness robust growth in the market, driven by a combination of factors. Increasing government expenditure on healthcare infrastructure and services underscores a commitment to improving public health outcomes. Concurrently, the region is experiencing rapid technological advancements, fostering innovation in medical treatments and diagnostic tools. Government initiatives aimed at promoting healthcare access and affordability further amplify the growth potential. This convergence of factors creates a fertile environment for sustained expansion in the market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Epigenetics Diagnostic Market Analysis

El panorama competitivo del mercado proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado.

Algunos de los principales actores que operan en el mercado son:

• Bio-Tecnología. (Estados Unidos)
• Corporación Promega (Estados Unidos)
• GeneTex, Inc. (Estados Unidos)
• PacBio (Estados Unidos)
• Illumina, Inc. (Estados Unidos)
• Merck KGaA (Alemania)
• QIAGEN (Alemania)
• F. Hoffmann-La Roche Ltd (Suiza)
• Eisai Co., Ltd. (Japón)
• Novartis AG (Suiza)
• Diagenode sa (EE.UU.)
• Active Motif, Inc. (Estados Unidos)
• Zymo Research Corporation (Estados Unidos)
• Thermo Fisher Scientific (Estados Unidos)
• Sindaxis (EE.UU.)
• Laboratorios Biológicos de Nueva Inglaterra (EE. UU.)
• Epizyme, Inc. (Estados Unidos)
• Domainex (Reino Unido)
• Agilent Technologies, Inc. (Estados Unidos)
• PerkinElmer Inc. (Estados Unidos)
• Laboratorios Bio-Rad, Inc. (Estados Unidos)
• AsisChem Inc. (Estados Unidos)
• Enzo Life Sciences, Inc. (Estados Unidos)
• EpiGentek Group Inc. (Estados Unidos)
• BioVision Inc. (Estados Unidos)

SKU-42187